According to Zhitong Finance App, Boan Biotech (06955.HK) announced that BA2201, a Class 1 innovative drug independently developed by the company, has been approved by the China National Drug Administration (NMPA) Drug Evaluation Center (CDE) to conduct clinical trials. The drug under development is a long-acting bispecific antibody targeting TL1A and IL-23 (p19), and is intended to treat autoimmune diseases such as inflammatory bowel disease (“IBD”).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.